These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20692809)

  • 21. Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders.
    Pary RJ
    Ment Retard; 1994 Oct; 32(5):323-7. PubMed ID: 7984116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
    N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine for refractory schizophrenia: the Illinois experience.
    Buckman RW; Malan RD
    J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine use in a forensic population in a New South Wales prison hospital.
    Martin A; O'Driscoll C; Samuels A
    Aust N Z J Psychiatry; 2008 Feb; 42(2):141-6. PubMed ID: 18197509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation.
    Wehmeier PM; Gebhardt S; Schmidtke J; Remschmidt H; Hebebrand J; Theisen FM
    Psychiatry Res; 2005 Feb; 133(2-3):273-6. PubMed ID: 15741002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of clozapine in adults with intellectual disability.
    Thalayasingam S; Alexander RT; Singh I
    J Intellect Disabil Res; 2004 Sep; 48(Pt 6):572-9. PubMed ID: 15312058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schizophrenia spectrum disorders in people with intellectual disabilities.
    Hemmings CP
    Curr Opin Psychiatry; 2006 Sep; 19(5):470-4. PubMed ID: 16874118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacoeconomics of clozapine: a review.
    Meltzer HY; Cola PA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():161-5. PubMed ID: 7961564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia.
    Kranzler H; Roofeh D; Gerbino-Rosen G; Dombrowski C; McMeniman M; DeThomas C; Frederickson A; Nusser L; Bienstock MD; Fisch GS; Kumra S
    J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):55-63. PubMed ID: 15608544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature.
    Deb S; Unwin GL
    Curr Opin Psychiatry; 2007 Sep; 20(5):461-6. PubMed ID: 17762588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
    Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
    Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine: an atypical antipsychotic agent.
    Ereshefsky L; Watanabe MD; Tran-Johnson TK
    Clin Pharm; 1989 Oct; 8(10):691-709. PubMed ID: 2572373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol-related problems in adolescents and adults with intellectual disabilities.
    Barrett N; Paschos D
    Curr Opin Psychiatry; 2006 Sep; 19(5):481-5. PubMed ID: 16874120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are CYP1A2*1F and *1C associated with clozapine tolerability?: a preliminary investigation.
    Bolla E; Bortolaso P; Ferrari M; Poloni N; Callegari C; Marino F; Lecchini S; Vender S; Cosentino M
    Psychiatry Res; 2011 Oct; 189(3):483. PubMed ID: 21481946
    [No Abstract]   [Full Text] [Related]  

  • 36. Isolated oculogyric crisis on clozapine discontinuation.
    Mendhekar DN; Duggal HS
    J Neuropsychiatry Clin Neurosci; 2006; 18(3):424-5. PubMed ID: 16963596
    [No Abstract]   [Full Text] [Related]  

  • 37. A Retrospective Review of the Use of Clozapine in Restoration of Competency to Stand Trial.
    Ghossoub E; Salem A; Minchin S; Hayreh D; Newman WJ
    J Am Acad Psychiatry Law; 2021 Mar; 49(1):42-48. PubMed ID: 33246989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine therapy in patients with neurologic illness.
    Sajatovic M; Ramirez L
    Int J Psychiatry Med; 1995; 25(4):331-44. PubMed ID: 8822385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness of clozapine for intellectual disability: Results from a mirror-image and a reverse-mirror-image study.
    Rohde C; Hilker R; Siskind D; Nielsen J
    J Psychopharmacol; 2018 Nov; 32(11):1197-1203. PubMed ID: 29944071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic drug side effects for persons with intellectual disability.
    Matson JL; Mahan S
    Res Dev Disabil; 2010; 31(6):1570-6. PubMed ID: 20580203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.